
Bioptimus is building the first universal AI foundation model for biology, aiming to capture the complex laws of biology for breakthrough discoveries and innovations in biomedicine and environmental science. They leverage a world-class team of engineers and research scientists with expertise in machine learning and biological data. Bioptimus benefits from strategic partnerships for high-volume, diverse, multimodal, and multiscale data, along with best-in-class GPU resources and a secure computing environment for training their models. Data security is a priority, enabling safe access and management of vast datasets. The company has launched H-optimus-1, a foundation model for pathology, and H-optimus-0, the world's largest open-source AI foundation model for pathology. They have also secured access to NVIDIA compute resources and are part of the FrenchTech Next 40/120 Program.

Bioptimus is building the first universal AI foundation model for biology, aiming to capture the complex laws of biology for breakthrough discoveries and innovations in biomedicine and environmental science. They leverage a world-class team of engineers and research scientists with expertise in machine learning and biological data. Bioptimus benefits from strategic partnerships for high-volume, diverse, multimodal, and multiscale data, along with best-in-class GPU resources and a secure computing environment for training their models. Data security is a priority, enabling safe access and management of vast datasets. The company has launched H-optimus-1, a foundation model for pathology, and H-optimus-0, the world's largest open-source AI foundation model for pathology. They have also secured access to NVIDIA compute resources and are part of the FrenchTech Next 40/120 Program.
Headquarters: Paris
Mission: Build universal multimodal AI foundation models for biology
Total disclosed funding: USD 76,000,000
Founded: 2024
Notable models: H-optimus-1 and H-optimus-0 (pathology foundation models)
Biomedical and environmental biological discovery using large-scale multimodal biological data
2024
Biotechnology Research
USD 35,000,000
USD 41,000,000
Follow-on financing bringing cumulative disclosed funding to USD 76M
“Participation from strategic life-science and tech investors including Sofinnova Partners, Cathay Innovation, Bpifrance, Andera Partners, Hitachi Ventures, Hummingbird Ventures, NJF Capital, Owkin, and others”
| Company |
|---|